Syndax Pharmaceuticals Inc

SNDXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1395937

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	$139.7M	$1.5M	$1.5M
Research and Development Expense	$163.0M	$118.5M	$88.2M	$50.4M	$43.0M
Selling, General and Administrative Expense	$66.9M	$33.3M	$25.2M	—	—
Operating Expenses	$230.0M	$151.8M	$113.5M	$72.9M	$59.1M
Operating Income (Loss)	-$230.0M	-$151.8M	$26.2M	-$71.4M	-$57.5M
Interest Expense	—	—	$1.9M	$2.4M	$2.4M
Nonoperating Income (Expense)	$20.6M	$2.4M	-$1.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$724.8M	$612.9M	$497.2M	$449.7M	$300.6M
Assets, Current	$603.1M	$580.9M	$489.8M	$448.4M	$298.9M
Cash and Cash Equivalents, at Carrying Value	$295.4M	$74.4M	$222.0M	$115.2M	$24.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$7.6M	$0.00	—	—	—
Inventory, Net	$366.0K	$0.00	—	—	—
Liabilities	$436.7M	$58.7M	$29.8M	$41.3M	$48.4M
Liabilities, Current	$103.5M	$58.1M	$29.1M	$20.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$160.6M	-$133.7M	$29.1M	-$71.3M	-$50.6M
Net Cash Provided by (Used in) Investing Activities	$117.6M	-$186.2M	-$40.9M	-$142.5M	$12.8M
Net Cash Provided by (Used in) Financing Activities	$264.1M	$172.3M	$118.5M	$304.4M	$28.6M
Payments to Acquire Property, Plant, and Equipment	$0.00	—	$129.0K	$0.00	$129.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)